摘要
目前乳腺癌已成为全世界女性最常见的恶性肿瘤之一,其发病率和死亡率在女性恶性肿瘤中位居第二。大量流行病学资料和临床研究表明体质量指数(BMI)与乳腺癌内分泌耐药关系密切。无论是绝经前或者绝经后的乳腺癌患者,升高的BMI均可导致无病生存期(DFS)和总生存期(OS)受损。体质量指数在乳腺癌内分泌治疗耐药机制中的作用有待进一步研究。个体化治疗可能是预防乳腺癌内分泌耐药的积极措施。本文回顾分析了BMI对绝经前和绝经后乳腺癌患者内分泌耐药的影响及可能的机制,希望对临床工作有所帮助。
Breast cancer is the most common malignancy among women and is the second leading cause of morbidity and mortality in female cancer.Large amounts of clinical studies and epidemiological data indicate that body mass index is closely associated with endocrine therapy resistance in breast cancer.Increased BMI leads to impaired disease-free survival and overall survival in pre-and postmenopausal patients with breast cancer.The futher research on the relationship between BMI and breast cancer endocrine resistance mechanism is in need.Individual treatment may be a positive measure to prevent breast cancer endocrine resistance.In this article,we reviewed the impact of BMI on endocrine therapy resistance in pre-and postmenopausal patients with breast cancer and its possible mechanism,hoping to be helpful in clinical work.
出处
《武汉大学学报（医学版）》
CAS
2016年第1期163-166,共4页
Medical Journal of Wuhan University
关键词
乳腺癌
内分泌耐药
体质量指数
Breast Cancer
Endocrine Resistance
Body Mass Index
